Wedbush Cuts PT on Garmin from $60 to $55 (GRMN)
Get Alerts GRMN Hot Sheet
Price: $295.67 -0.6%
Rating Summary:
7 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 9 | New: 24
Rating Summary:
7 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 9 | New: 24
Join SI Premium – FREE
Wedbush Morgan lowers its price target on Garmin (Nasdaq: GRMN) from $60 to $55 and reiterates its Buy rating.
The firm said it was surprised with Garmin's strong margin levels during Q1, and believes this slightly offset revenues and EPS that were slightly lower-than-expected. Additionally, Wedbush notes Garmin management's confidence in being able to achieve its original FY08 guidance.
Wedbush calls Garmin a "good value play" due to a "very attractive valuation and continued growth in revenue and profits."
Notably, Wedbush's new price target on Garmin still represents about a 31% return from today's price of around $42.
Garmin, Ltd. and its subsidiaries design, develop, manufacture, and market global positioning system (GPS)-enabled products and other related navigation, communications, and information products worldwide. [BCS]
The firm said it was surprised with Garmin's strong margin levels during Q1, and believes this slightly offset revenues and EPS that were slightly lower-than-expected. Additionally, Wedbush notes Garmin management's confidence in being able to achieve its original FY08 guidance.
Wedbush calls Garmin a "good value play" due to a "very attractive valuation and continued growth in revenue and profits."
Notably, Wedbush's new price target on Garmin still represents about a 31% return from today's price of around $42.
Garmin, Ltd. and its subsidiaries design, develop, manufacture, and market global positioning system (GPS)-enabled products and other related navigation, communications, and information products worldwide. [BCS]
You May Also Be Interested In
- UBS Upgrades Sartorius AG (SRT3:GR) (SARTF) to Buy
- UBS Upgrades Sartorius Stedim Biotech (DIM:FP) (SDMHF) to Buy
- UBS Downgrades Merck (MRK) to Neutral
Create E-mail Alert Related Categories
Analyst Comments, Insiders' BlogRelated Entities
Wedbush Morgan, Scopia CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share